As the company ramps up, Exciton’s wound-management technology is attracting attention as an innovative way to reduce pain and promote healing. Direct marketing, clinical research and the signings of major license and distribution agreements have caught everyone’s attention.

Exciton’s bandages and wound coverings, with a unique silver ingredient (Ag. Oxysalts) and a proprietary line of exsalt® wound care products, are now being discovered by the global medical community.

01

After years of struggling, Exciton did $1.3 million in sales last year. President and Founder Rod Precht is on track to gross $2.5 to $3 million in 2015.

The company has grown from two employees in 2008 to 20 today. It manufactured and shipped 15,000 wound dressings a month in 2014. By the end of 2015, that figure will jump to 50,000 wound dressings a month.

“I can’t say enough about how TEC hung in with Exciton,” says Rod. “We’ve been under the TEC umbrella for many years. TEC helped us find investors, provided strategic direction, mentoring and the TEC Centre space complete with labs and the flexibility to expand. Now TEC is helping us with marketing strategies for the company as a whole.”

“It’s been a survival story,” grins Precht. “We knew we had the product, with one of the best antibacterial performances at 30-to-50% less cost than the competition.

“It took a lot of time and trial and error to find the right mix – to concentrate on manufacturing and research & development, to let our distributors  (Crawford Healthcare overseas and in the USA, Cardinal Health in Canada) handle marketing and sales.”

Precht’s entrepreneurial spirit grows stronger with time. He’s convinced, through internal and external research that harnessing the active ingredients in Exciton’s Oxysalts will provide medical benefits beyond wound dressings, that those “active ingredients” could one day be classed as a drug.

“My dream,” he says, “is to have $87 million in revenues within five years.”